Efficacy vs. effectiveness — docetaxel and prednisone in hormone refractory prostate cancer

Abstract

Objectives. To assess the clinical effectiveness of docetaxel and prednisone in a clinical setting and to compare the results to those seen in the pivotal clinical trial. To assess the impact of various factors on the prognosis of patients treated with docetaxel.

Design. Retrospective chart review. The primary outcome measured was survival. Survival data was analyzed through the Kaplan—Meier methodology. A multivariate analysis of prognostic variables was also conducted.

Setting. Public cancer centers within the Canadian province of Alberta.

Patients. Hormone refractory, metastatic prostate cancer patients initiated on docetaxel chemotherapy between September 2004 and February 2007 within the Alberta Cancer Board.

Main Outcome Measured. The primary outcome measured was median survival.

Results. Among 161 patients eligible for review, median survival was 17.22 months. Chemotherapy received after docetaxel was determined to be a significant favorable prognostic factor for survival ( p<0.0001).

Conclusion. In a clinical setting, docetaxel and prednisone did not perform as well in terms of median survival, as it was shown to in prior clinical trials (17.22 vs. 18.9 months). Further investigation into the impact of docetaxel and prednisone on quality of life in clinical practice, would complement the findings of this study. J Oncol Pharm Practice (2008) 14: 45—49.

Keywords

effectiveness docetaxel prostate cancer

Get full access to this article

View all access options for this article.

References

Prostate Cancer Stats: Canadian Cancer Society; [2007 April 11; cited 2007 May 24]. Available from: http://www.cancer.ca/ccs/internet/standard/0,2283,3172_14471__langId-en,00.html

Cancer Management Guidelines. Prostate: BC Cancer Agency; [2006 June; cited 2007 May 30]. Available from: http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Genitourinary/Prostate/Management/default.htm

Loblaw DA , Virgo KS , Nam R. et al. Initial hormonal management of androgen-sensitive metastatic, recurrent or progressive prostate cancer: 2006 update of an american society of clinical oncology practice guideline. J Clin Oncol 2007; 25: 1596—605.

Berry W. , Dakhil S. , Modiano M. , Gregurich M. , Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002; 168: 2439—43.

Kantoff PW , Halabi S. , Conaway M. et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999; 17: 2506—13.

Tannock IF , Osoba D. , Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756—64.

Petrylak DP , Tangen CM , Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refactory prostate cancer. N Engl J Med 2004; 351: 1513—20.

Tannock IF , de Wit R. , Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 ; 351: 1502—12.

Guidelines for the economic evaluation of health technologies: Canada [3rd Edition]. Ottawa : Canadian Agency for Drugs and Technologies in Health ; 2006.